開催日: 2026年6月30日 (火曜日)
開催時間: 12:00 PM – 2:00 PM
開催場所: Basel Marriott Hotel, Messepl. 25, 4058 Basel, Switzerland
Join internationally recognized leaders in Model-Informed Drug Development (MIDD), Piet van der Graaf and Karen R. Yeo, for an intimate, in-person, and highly interactive Lunch & Learn during ISSX Basel 2026.
This invite-only session brings together a select audience of scientists and drug development leaders for a focused discussion on how mechanistic approaches and strong scientific foundations are shaping regulatory success in modern drug development.
Both speakers have played leading roles in advancing quantitative and translational sciences across industry, academia, and regulatory engagement, and have also served as Editors-in-Chief of Clinical Pharmacology & Therapeutics (CPT), helping define scientific standards and thought leadership across the field.
お申込みはこちら
Registrations are subject to review and approval
Piet van der Graaf
Senior Vice President, Head of QSPPiet van der Graaf, PharmD, PhDは、サターラのApplied BioSimulation担当シニアバイスプレジデントであり、 Leiden University システム薬理学教授、 Cincinnati Children’s Hospital Medical Center 小児科教授を務めています。Previously, he was the Director of the Leiden Academic Centre for Drug Research and held leadership positions at Pfizer in Discovery Biology, DMPK and Clinical Pharmacology. CPTの創刊編集長であり、Pharmacometrics & Systems Pharmacology before becoming Editor-in-Chief of Clinical Pharmacology & Therapeutics. Pietはロンドン大学キングス・カレッジにてノーベル賞受賞者サー・ジェームズ・ブラックのもとで臨床医学の博士課程を修了し、He was awarded the 2024 Gary Neil Prize for Innovation in Drug Development from the American Society of Clinical Pharmacology and Therapeutics (ASCPT) and the 2021 Leadership Award from the International Society of Pharmacometrics (ISoP). 英国薬理学会のフェローに選出されており、これまで定量的薬理学および医薬品開発の分野にて250本以上の論文を発表しています。
Karen Rowland Yeo, PhD
Senior Vice President, Client & Regulatory StrategyKarenは、サターラUK LimitedのSimcyp Divisionにおいて、Client & Regulatory Strategy担当シニアバイスプレジデントを務めています。Prior to this, she was the Head of PBPK Consultancy Services at Simcyp where she led a team of scientists engaged in Consultancy projects relating to the application of physiologically based pharmacokinetic (PBPK) modelling in drug development. Her work has focused on the use of PBPK models for assessment of drug-drug interactions and dosing of special populations and she is the author/co-author of more than 100 peer reviewed articles in these areas.
お申込みはこちら
Registrations are subject to review and approval
関連コンテンツ
From first-in-human trials to global regulatory approvals and post-launch, Certara solutions can help you move your science forward faster, with confidence.
